Table 2.
Medications were stable between visits before and after DC cardioversion
| Before DC | 12 ± 3 days after DC | Before DC | 12 ± 3 days after DC | |
|---|---|---|---|---|
| Nonresponders (n = 55) | Responders (n = 56) | |||
| Waran | 55 (100) | 55 (100) | 56 (100) | 56 (100) |
| Digoxin | 12 (22) | 8 (15) | 9 (16) | 6 (11) |
| Amiodarone | 5 (9) | 5 (9) | 6 (11) | 6 (11) |
| Sotalol | 15 (27) | 13 (24) | 12 (21) | 15 (27) |
| β-blocker | 26 (47) | 31 (56) | 35 (63) | 32 (57) |
| Diuretics | 22 (40) | 21 (38) | 13 (23) | 16 (29) |
| Lipid-lowering drug | 15 (27) | 16 (29) | 22 (39) | 20 (36) |
| ARB | 10 (18) | 9 (16) | 8 (14) | 9 (16) |
| ACE-I | 10 (18) | 12 (22) | 18 (32) | 19 (34) |
| Calcium blocker | 10 (18) | 11 (20) | 8 (14) | 7 (13) |
| Potassium | 4 (7) | 5 (9) | 1 (2) | 2 (4) |
| Spironolactone | 3 (5) | 4 (7) | 4 (7) | 5 (9) |
| Sleep and Sedatives | 9 (16) | 8 (15) | 6 (11) | 6 (11) |
Percent within brackets
ARB angiotensin II receptor antagonist, ACE-I angiotensin-converting enzyme inhibitor